Register to receive a free US Market Report Suite for Orthopedic Soft Tissue Repair and Sports Medicine report synopsis and brochure

Arcuro Medical Ltd. (“Arcuro”), a portfolio company of The Trendlines Group Ltd. (“Trendlines”), announced that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBall™ meniscus repair system.

Meniscus tears are a common occurrence in many population groups: professional athletes, people who engage in daily sport activities, the ageing population, and people predisposed to cartilage problems.

To maintain knee functionality, current practice seeks to avoid removal of the meniscus, and prefers arthroscopic repair techniques. Shortcomings of current repair devices, however, include rigid implants, difficult-to-use delivery systems, and leave a knot in the joint space. These can cause poor repair quality, increased intraoperative failure, long-term damage to the meniscus, and device failures.

Arcuro has developed an all-suture meniscus repair system that preserves knee functionality and is secure, reliable, and effective. Arcuro completed an extensive and very successful series of pre-clinical studies in the United States and Israel. The Company believes that with its easy-to-use system, an all-suture implant, with no knot in the joint space, more surgeons will confidently choose to repair the meniscus instead of removing it. As a result, Arcuro expects to convert a significant portion of the meniscus removal procedures performed annually to repair procedures.

Arcuro submitted a patent at national phase in China, Israel, the United States, and Europe. The patent in the United States was recently granted.

“We are very excited to have achieved FDA clearance in addition to the news of receiving our US patent. These two important milestones will enable the company to begin its clinical evaluation phase straight away,” remarked Lee Ranon, CEO of Arcuro.

Chairman and CEO of The Trendlines Group, Steve Rhodes added: “We are very proud of the progress that the Arcuro team has made towards bringing their SuperBall™ meniscus repair system to market. We look forward to following their progress in improving patient outcomes and reducing surgeries in a market seeking a solution to this common and painful problem.”

Source: https://www.prnewswire.com/news-releases/arcuro-medical-receives-fda-regulatory-clearance-300667605.html

For Further Information

More on the orthopedic soft tissue repair market in the U.S. can be found in a series of reports published by iData Research entitled the U.S Market Report Suite for Orthopedic Soft Tissue Repair and Sports Medicine. The suite covers reports on the following markets: tendon reinforcement grafts, suture anchors, tenodesis screws, ACL/PCL replacement allografts, interference screws, intratunnel fixation devices, cortical fixation devices, cross-pins, washer and post, osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, particulated juvenile allograft implant, microfracture adjunct, suture meniscal repair devices, implant meniscal repair devices, hybrid meniscal repair devices, hip radiofrequency probes, banana blades, hip access kits and disposable suture passers.

The iData report series on orthopedic soft tissue repair covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about orthopedic soft tissue repair market data, register online or email us at [email protected] for a U.S Market Report Suite for Orthopedic Soft Tissue Repair and Sports Medicine brochure and synopsis.